Primary percutaneous coronary intervention (PCI) is the treatment of choice for patients with ST-elevation myocardial infarction (STEMI) since it results in greater patency of the infarct-related artery (IRA) and lower rates of re-infarction, stroke and death when compared with fibrinolysis alone. Multivessel disease (MVD) occurs in 40% to 65% of patients with STEMI. Is it possible for an aggressive multivessel percutaneous revascularization strategy to afford advantages in greater myocardial salvage and avoidance of staged procedures, with subsequent savings in compounded procedural risks? ...(excerpt
